Q-omics provides the consensus-scored PSMB2 profile across patient tissues and cancer cell-line models. PSMB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PSMB2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PSMB2 protein abundance shows 29,563 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, HNSC, and LUAD as cancer lineages where PSMB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMB2 survival associations across molecular data types. PSMB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMB2 RNA expression–survival associations across cancer types. High PSMB2 expression shows unfavorable associations in LIHC, ACC, MESO, LGG and KIRP, but favorable associations in COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PSMB2 RNA expression.
This table summarizes PSMB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMB2 shows higher tumor expression in HNSC, KIRC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher PSMB2 RNA expression in tumor versus normal tissue (log2 FC = +1.118, t-test p < 0.001).
This table shows molecular features associated with PSMB2 in patient tissues and cancer cell lines. In patient samples, PSMB2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
